Armata Pharmaceuticals, Inc. (ARMP)

[longmike2]

APHB trading volume has added 1043024 shares compared to readings over the past three months as it recently exchanged 1224404 shares. This means there is improved activity from short-term traders as per session, its average trading volume is 181380 shares, and this is 6.75 times the normal volume. A look at its technical analysis shows that its 14-day Relative Strength Index (RSI) is in a oversold zone after reaching 27.93 point.

AmpliPhi Biosciences Corporation (NYSE:APHB) dipped by -46.35% over the past three months which led to its overall six-month decrease to stand at -49.14%. The equity price sank -46.36% this week, a trend that has led to both investors and traders taking note of the stock. A look at its monthly performance shows that its shares have recorded a -38.86% fall over the past 30 days. Over the past 12 months the stock has embarked on a drop that has seen it decline -45.5% and is now down by -41.58% since start of this year.

The shares of AmpliPhi Biosciences Corporation dropped by -71.22% or -$1.46 from its last recorded high of $2.05 which it attained on January 08 to close at $0.59 per share. Over the past 52 weeks, the shares of AmpliPhi Biosciences Corporation has been trading as low as $0.59 before witnessing a massive surge by 0% or $0. This price movement has led to the APHB stock receiving more attention and has become one to watch out for. It dipped by -13.24% on Wednesday and this got the market worried. The stock’s beta now stands at 1.36 and when compared to its 200-day moving average and its 50-day moving average, APHB price stands -48.55% below and -41.9% below respectively. Its average daily volatility for this week is 21.6% which is more than the 13.41% recorded over the past month.

Experts from research firms are bullish about the near-term performance of AmpliPhi Biosciences Corporation (APHB) with most of them predicting a $6 price target on a short-term (12 months) basis. The average price target by the analysts will see a 916.95% rise in the stock and would lead to APHB’s market cap to surge to $100.08M. The stock has been rated an average 2, which roughly stands towards the bullish end of the spectrum. Reuters looked into the 1 analysts that track AmpliPhi Biosciences Corporation (NYSE:APHB) and find out that 0 of them rated it as a Hold. 1 of the 1 analysts rated it as a Buy or a Strong Buy while 0 advised investors to desist from buying the stock or sell it if they already possess it.